Patent Number: 6,762,199

Title: Indane derivatives

Abstract: The invention is directed to physiologically active compounds of general formula (I): ##STR1## wherein: R.sup.1 represents aryl, heteroaryl or a group R.sup.3 --L.sup.2 --Ar.sup.1 --L.sup.3 --; R.sup.2 represents hydrogen or lower alkyl; R.sup.3 represents aryl or heteroaryl; and Ar.sup.1 represents an optionally substituted saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (.alpha.4.beta.1).

Inventors: Fenton; Garry (West Malling, GB), McCarthy; Clive (West Malling, GB), MacKenzie; Robert Edward (West Malling, GB), Morley; Andrew David (West Malling, GB)

Assignee: Aventis Pharma Limited

International Classification: C07D 235/00 (20060101); C07D 235/30 (20060101); C07D 263/58 (20060101); C07D 263/00 (20060101); A61K 031/423 (); C07D 263/54 ()

Expiration Date: 07/13/2021